ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 118 for:    Recruiting, Not yet recruiting, Available Studies | "Hypertension, Pregnancy-Induced"

Catestatin and Hypertension in Pregnancy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03200743
Recruitment Status : Recruiting
First Posted : June 27, 2017
Last Update Posted : June 27, 2017
Sponsor:
Information provided by (Responsible Party):
Yuchen Pan, Peking University Third Hospital

Brief Summary:
Catestatin is a kind of protein involved with cardiovascular disease. Accumulated evidence shows that Catestatin may be a predictor of primary hypertension, but whether it plays the same role in pregnant hypertensive disorders needs to be determined. By measuring the plasma level of Catestatin, main biochemical marks and UCG in healthy pregnancy and pregnancy with hypertension, the research may contribute to this problem.

Condition or disease
Pre-Eclampsia Eclampsia Hypertension, Pregnancy-Induced Hypertension in Pregnancy

Study Type : Observational [Patient Registry]
Estimated Enrollment : 400 participants
Observational Model: Case-Control
Time Perspective: Prospective
Target Follow-Up Duration: 18 Years
Official Title: Relationship Between Catestatin and Pregnant Hypertensive Disorders
Actual Study Start Date : May 14, 2017
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort
Hpertension
Health



Primary Outcome Measures :
  1. plasma level of Catestatin [ Time Frame: once at the specified enrollment period ]
    plasma level of Catestatin with the unit "mmol/l"


Secondary Outcome Measures :
  1. blood pressure [ Time Frame: the specified enrollment period,42 days and 2 months after the pregnancy ]
    systolic and diastolic blood pressure with the unit "mmHg"


Biospecimen Retention:   None Retained
Plasma


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients hospitalized in Peking University Third Hospital maternity ward after May, 2017
Criteria

Inclusion Criteria:

  • Healthy pregnancy women
  • Pregnancy women with hypertension

    1. Despite the pregnant gestational age , systolic blood pressure ≥140 mm Hg OR a diastolic blood pressure of ≥90 mm Hg measured three times more than 24 hours apart
    2. Pregnant gestational age > 20 weeks, systolic blood pressure ≥140 mm Hg OR a diastolic blood pressure of ≥90 mm Hg measured twice more than 4 hours apart

Exclusion Criteria:

  • Lack of blood sample at the specified enrollment period
  • Women who refuse the study
  • Other illness which needs medications interfering with blood pressure (eg: Asthma requiring systemic steroids)
  • Known coronary artery disease or heart failure
  • Serious medical illness (eg: renal insufficiency, congestive heart disease, chronic respiratory insufficiency, uncontrolled infection).
  • multiple endocrine neoplasia or Cushing's syndrome or mixed tumours or pheochromocytoma or medullary thyroid carcinoma.
  • previous history of malignant tumour, with the exception of carcinoma in situ of the uterine cervix or non-melanoma skin cancer
  • renal insufficiency

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03200743


Contacts
Contact: Yuchen Pan, MD +8618810533382 panyuchen@bjmu.edu.cn
Contact: Dan Zhu, MD andrea_zhu@163.com

Locations
China, Beijing
Peking University Third Hospital Recruiting
Beijin, Beijing, China, 100191
Contact: Yuchen Pan, MD    +8618810533382    panyuchen@bjmu.edu.cn   
Contact: Dan Zhu, MD       andrea_zhu@163.com   
Sponsors and Collaborators
Yuchen Pan

Responsible Party: Yuchen Pan, Peking University Third Hospital
ClinicalTrials.gov Identifier: NCT03200743     History of Changes
Other Study ID Numbers: 20170513
First Posted: June 27, 2017    Key Record Dates
Last Update Posted: June 27, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Yuchen Pan, Peking University Third Hospital:
Hypertension
Pregnancy
Catestatin

Additional relevant MeSH terms:
Hypertension
Eclampsia
Pre-Eclampsia
Hypertension, Pregnancy-Induced
Vascular Diseases
Cardiovascular Diseases
Pregnancy Complications